Services Clinical Development Strategy

Clinical development strategy

Navigate high-stakes trial decisions with clarity. Scitaris combines deep scientific expertise and curated data to help you advance programs with confidence.

Start the conversation

From uncertainty to direction

Scitaris applies structured, science-led analysis to guide clinical development, ensuring strategies are grounded in evidence and built to withstand investor and regulatory scrutiny.

84% trial prediction accuracy

Our science-driven models correctly predict clinical efficacy trial outcomes with 84% accuracy

100+ strategies delivered

We have guided more than 100 biotech and pharma teams with full development strategies

Biomarker data at scale

Terabytes of biomarker datasets analyzed to design trials with better stratification and precision

Drug repurposing search

Scitaris identifies molecules with proven safety profiles that can be redirected into new indications. Using proprietary algorithms and expert review, we surface translatable assets that expand your pipeline without starting from scratch.

Indication search & development strategy

Our systematic framework screens 21k+ indications, prioritizing those with the strongest biological rationale and development feasibility. We integrate factors like biomarker hypotheses and company-specific constraints to create a clear, data-driven clinical development strategy.

Biomarker identification and screening

We help design clinical trials that stratify patients effectively. From biomarker discovery through validation, our team ensures endpoints are scientifically grounded and positioned to generate meaningful, decision-driving clinical readouts.

Clinical development challenge

A mid-sized pharmaceutical company advanced a compound with potential across several disease areas but lacked a clear path to selecting the strongest indication.

Scitaris solution

We applied a science-driven indication screening across 21,000+ diseases, integrating target biology, feasibility, and commercial potential to highlight the strongest opportunities.

Results

The client adopted our recommended strategy, balancing risk, reward, and time-to-market. The prioritized development led to successful financing and generation of highly competitive clinical data.

Stefanos Theoharis

CEO of OneChain Immunotherapeutics (former CBO, Bone Therapeutics S.A.)

I worked with the Scitaris team on an extensive portfolio review exercise. My colleagues and I found the team to be very diligent, meticulous, knowledgeable and systematic, delivering work of the highest quality in a complex field.

They were engaged, proactive and took an efficient approach which yielded a very useful report that we continue to use to this day as a decision-making tool. I look forward to working with them at another opportunity and would highly recommend Scitaris.

Andrew Sklawer

Co-founder & COO, Brickell Biotech Inc.

I could write a novel about how great you and your team are, but will keep it short and sweet: Thank you from the bottom of our hearts. We value the Scitaris team tremendously and really appreciate everything you have done in going above and beyond for us.

Emmanuel Coeytaux

COO, DRI Healthcare (former CEO, Steba Biotech Inc.)

We were fortunate to be introduced to the Scitaris team to work on the articulation of the vision and strategy for our oncology platform. The immediate outcome was a very successful business development discussion where our partner was excited about our company and projects.

The longer-term outcome is the creation of a simple and compelling framework to organize and prioritize our clinical development programs. Beyond this, the Scitaris team was a pleasure to work with and we look forward to having them as an enduring advisor to our team.

Jørgen Søberg Petersen

Senior Partner, Novo Holdings

The unique combination of strong analytical skills, strategic thinking, systematic use of methodology, and excellent people skills makes Jonathan [Scitaris co-founder] exceptionally qualified to support organizations with complex business problems.

He’s a result-driven and constructive individual that delivers high-quality work with focus on implementation and business execution.

FAQs

What modalities or therapeutic areas do you specialize in?

We can support across all modalities and therapeutic areas. Our team has deep experience spanning small molecules, biologics, cell and gene therapies, and rare diseases.

What type of projects or deliverables can you support?

We support clients throughout the clinical development process, helping shape indication strategies, design trials, refine biomarker and endpoint choices, and prepare decision-ready materials that stand up to board and regulatory scrutiny.

Do you support different global or regional regulatory strategies?